- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FCS Adds New In-House, Precision Oncology Capabilities
Florida Cancer Specialists & Research Institute announced the formation of additional precision oncology capabilities and resources comprised of geneticists, informatics specialists, and database technologies that will enhance patient care through comprehensive analysis of molecular data.
Fort Myers, Florida — Florida Cancer Specialists & Research Institute (FCS) recently announced the formation of additional precision oncology capabilities and resources to enhance patient care through comprehensive analysis of molecular data.
Comprised of geneticists, informatics specialists, and database technologies, the newly formed FCS Precision Oncology Informatics Team is focused on facilitating and streamlining the delivery of real-world data (RWD) and real-world evidence (RWE). The enhanced data collection provided to FCS physicians, researchers, and drug development teams seeks to enable optimized decision-making related to targeted treatment options and clinical trial matches.
“Being on the leading edge of healthcare, through investments in precision medicine, novel treatment pathways, and a steadfast commitment to delivering value-based care throughout the state, where and when our patients need us, regardless of age, gender, race, ethnicity, identify, or any social status is ingrained in our core strategy as a practice,” said Nathan H. Walcker, MBA, chief executive officer of FCS.
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More
